Piper Sandler on March 04, 2026 maintained Overweight on Arcturus Therapeutics Holdings Inc. (ARCT). The ARCT analyst rating move kept a positive stance even as Piper Sandler noted a lower firm-level price view in a broader biotech reset. This action followed the firm’s note titled ‘2026 will be a stock-moving year for ArthroCare (ARTC)’, which referenced sector dynamics that also affect small-cap RNA therapeutics. Investors should view this maintained Overweight as continuity in conviction, not a fresh upgrade or downgrade

ARCT analyst rating: What Piper Sandler did on March 04, 2026

Piper Sandler maintained an Overweight rating on Arcturus Therapeutics Holdings Inc. (ARCT) on March 04, 2026. The firm left the rating unchanged while publishing commentary that included a lowered price opinion for a related name, signaling selective caution across its coverage. The StreetInsider report captured the firm’s view and the context around the rating source

Price targets and market context for ARCT analyst rating

Citigroup set a $8.00 price target for ARCT on March 04, 2026 according to Benzinga, implying modest upside. The broader consensus shows 26 analyst firms reporting on ARCT in the last year, which gives context to any single firm’s maintained rating. Investors should weigh Piper Sandler’s Overweight alongside the Citigroup price target and the full analyst cohort source

Immediate market reaction and price action

Public reporting tied to the Piper Sandler note showed a short-term price move of -4.17% ($-0.33) in the tracked mention. A maintained Overweight usually limits sharp intraday swings, but the cited price drift reflects sector noise and related firm commentary. Traders may see this as a signal to watch catalysts rather than a reason to change long-term positions

Historical analyst coverage and how this compares

The last upgrade for Arcturus occurred on May 11, 2023, when HC Wainwright & Co. raised its target to $51. Piper Sandler’s maintained Overweight keeps ARCT inside a mixed coverage landscape where price targets range widely. This history shows analysts alternate between high-conviction bullish calls and cautious revisions, driven by clinical readouts and balance sheet updates

What the ARCT analyst rating change means for investors

A maintained Overweight is a hold-constructive signal that favors accumulation on weakness for risk-tolerant investors. It is not a fresh upgrade or downgrade, so investors should focus on catalysts named by management, including the 12-week Phase II cystic fibrosis trial and regulatory timelines. Risk-averse holders may wait for clearer clinical or revenue signals before adding exposure

Meyka grade, market cap, and how we frame the view

Meyka AI rates ARCT with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Arcturus Therapeutics Holdings Inc. shows a market cap of $215,380,235, and our grade signals balanced opportunity with clinical and execution risk. Meyka’s AI-powered market analysis suggests watching upcoming clinical milestones and cash runway when comparing the Overweight stance to other firms

Final Thoughts

Piper Sandler’s March 04, 2026 decision to maintain Overweight on Arcturus Therapeutics Holdings Inc. (ARCT) keeps the stock in a favored category among this firm’s coverage while acknowledging sector headwinds. The ARCT analyst rating did not change, but related commentary lowered some expectations elsewhere in Piper Sandler’s biotech coverage. Investors should interpret this as continuity of conviction from Piper Sandler rather than a renewed bullish push. Combine this maintained rating with the latest Citigroup $8.00 price target, the fact that 26 analysts covered ARCT in the last year, and the stock’s $215,380,235 market cap. Short-term traders may react to headlines and intra-day volatility, while longer-term investors should track clinical catalysts, cash runway, and upcoming regulatory milestones. Meyka AI rates ARCT with a grade of B to reflect mid-tier risk and upside potential based on benchmarks, sector performance, growth metrics, and consensus. These grades are not guaranteed and are not financial advice

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.